Category: St. Jude Medical
Abiomed unveils new results from an IDE study of its Impella Right Percutaneous heart pump, reporting 73% survival in patients with right ventricular failure.
Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.
Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.
New data from CardioMEMs CHAMPION clinical trial shows that the company's implanted pulmonary artery pressure monitor helps reduce heart failure hospitalizations without compromising kidney function in patients with renal failure.
St. Jude Medical (NYSE:STJ) subsidiary CardioMEMs touted new study results this week showing that its implanted heart monitor is safe and effective in patients with chronic kidney disease.
A roundup of studies released at the annual Transcatheter Cardiovascular Therapies conference in Washington this week.
Here's a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:
Transcatheter aortic valve implants take center stage at the annual Transcatheter Cardiovascular Therapeutics conference with the latest data dumps from rivals Medtronic and Edwards Lifesciences.
St. Jude Medical hits 'pause' on implantations of its Portico replacement heart valve after CT scans turned up a potential problem with the devices.
Here's a look at some of the top Wall Street stories for medical device companies this week: Renal denervation isn't dead, despite Medtronic trial's failure; Baxter says HQ will stay in Illinois, stays coy on Boston plans; Private equity owners rebrand KCI, Systagenix, LifeCell as Acelity
, Apax Partners
, Baxter International
, Boston Scientific
, Centaur Guernsey
, Kinetic Concepts Inc.
, Kona Medical
, LifeCell Corp.
, ReCor Medical
, St. Jude Medical
, Systagenix Wound Management Inc.
St. Jude Medical says that its Quartet quadripolar leads "performed better than bipolar leads of any kind" in a recent mega-study.
Medical device giant St. Jude Medical (NYSE:STJ) had high praise for its own quadripolar leads, saying that blow away any competition from older bipolar leads.